RKER-216

N/A

Report date: 2024/11/12 15:24:07

Base Information

Drug NameRKER-216
Drug Alias NameRKER-216
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionActivin receptor type-1 inhibitorsMothers against decapentaplegic homolog 1 inhibitorsMothers against decapentaplegic homolog 5 inhibitors +[4] 
TargetsActivin receptor type-1Mothers against decapentaplegic homolog 1Mothers against decapentaplegic homolog 5 +[4] 
Therapy Area/IndicationsAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKeros Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKeros Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A